Table 1.
CEA vaccine studies in mice.
| Mouse Model | Effector cells | Effect on mice | Ref | |
|---|---|---|---|---|
| Protein based vaccines-preclinical trials | ||||
| bV-CEA/DOTAP | MC38-CEA-2 cells in C57BL/6 mice | Antibodies and T-cells | Protection from tumor challenge (70% of mice) | 23 |
| CpG-ODN plus Tat-CEA fusion protein | MC38-CEA-2 cells in C57BL/6 mice | CTLs and IgG | Prolongation of survival time (70% of mice), reduction of tumor volume (100% of mice) | 24 |
| CEA+/HS-Exo | HLA-A2.1/Kb transgenic mice | CTLs | No effect | 25 |
| DNA based vaccines alone-preclinical trials | ||||
| Prime (hCEA/DNA)-boost (GM-CSF/DNA) | MC38-CEA in CEA-tg C57BL/6 mice | CTLs | Reduced tumor volume (50%) | 36 |
| hCEA/DNA (pKCEA66 plasmid encoding a truncated hCEA form) | SCID mice with spleen cells from immunized d C57BL/6 mice and inoculated with hCEA expressing cells. | IgG, IFN-γ, T cell responses, NK cells | Suppression of tumor growth (60%) | 37,120 |
| hCEA/DNA (pCD40LT-CEA) | MC38-CEA in CEA-tg C57BL/6J mice | CTLs and DCs | Rejection of tumor challenge (50%) | 46 |
| hCEA/DNA (pCMV-CEA) plus IL-12/DNA (VR-IL-12) | CEA/LLC* cells in C57BL/6 mice | Antibodies, CTLs and IFN-γ | Suppression of tumor growth (80%) | 42 |
| hCEA/DNA (pCMV-CEA) plus IL-12/DNA (VR-IL-12) membrane bound | CEA/LLC* cells in C57BL/6 mice | Antibodies, CTLs and IFN-γ | Reduction of tumor incidence (40%) | 121 |
| Recombinant vector-based vaccines-preclinical trials | ||||
| ALVAC-CEA | MC38-CEA cells in C57BL/6 mice | CD4+ T cells, IgG, IFN-γ,IL-5 | Suppression of tumor growth (100%) | 122 |
| Ad5 [E1-, E2b-]-CEA | MC38-CEA-2 cells in C57BL/6 mice | IFN-γ and IL-2 | Regression of tumor growth (100% of mice) | 65 |
| Prime (rV/-CEA/TRICOM)-boost (yeast-CEA) | LL2-CEA tumor cells in CEA tg mice | CTLs | Reduction in pulmonary metastasis | 123 |
| rV-CEA/TRICOM plus GM-CSF and IL-2 | MC38-CEA cells in CEA tg mice | CTLs | Prolongation of survival time (83% of mice) | 92 |